Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arsanis Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Arsanis Raises USD45.5 Million in Series D Financing 11
Arsanis Raises USD15 million in Venture Financing 13
Arsanis Raises USD4 Million Financing 14
Arsanis Raises US$20 Million In Series B Financing 15
Licensing Agreements 17
BB200 Enters into Licensing Agreement with Arsanis 17
BB100 Enters into Licensing Agreement with Arsanis 18
Arsanis Enters into Licensing Agreement with Adimab 19
Equity Offering 20
Arsanis Raises USD46 Million in IPO of Shares 20
Arsanis Raises USD20 Million in Private Placement of Shares 22
Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23
Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24
Debt Offering 25
Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25
Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26
Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27
Arsanis Inc – Key Competitors 28
Arsanis Inc – Key Employees 29
Arsanis Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 13, 2018: Arsanis Reports Financial Results for Second Quarter 2018 31
May 10, 2018: Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 33
Mar 09, 2018: Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 35
Corporate Communications 37
Oct 04, 2017: Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer 37
Product News 38
04/17/2018: Arsanis to Present Abstract On ASN500 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 38
04/17/2018: Arsanis to Present Poster On ASN100 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 39
Clinical Trials 40
Oct 09, 2017: Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek 2017 40
Sep 08, 2017: Arsanis Presents Preclinical Data on Lead Product Candidate, ASN100, at the “2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance” 41
Apr 20, 2017: Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Disease 42
Jan 24, 2017: Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus Aureus Pneumonia 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
Arsanis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arsanis Raises USD45.5 Million in Series D Financing 11
Arsanis Raises USD15 million in Venture Financing 13
Arsanis Raises USD4 Million Financing 14
Arsanis Raises US$20 Million In Series B Financing 15
BB200 Enters into Licensing Agreement with Arsanis 17
BB100 Enters into Licensing Agreement with Arsanis 18
Arsanis Enters into Licensing Agreement with Adimab 19
Arsanis Raises USD46 Million in IPO of Shares 20
Arsanis Raises USD20 Million in Private Placement of Shares 22
Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23
Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24
Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25
Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26
Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27
Arsanis Inc, Key Competitors 28
Arsanis Inc, Key Employees 29
Arsanis Inc, Subsidiaries 30
List of Figures
Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9